Aclaris Therapeutics (ACRS) Files $86.25M Common Stock IPO

Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed a registration with the U.S. SEC for an IPO of its Common Stock. The proposed maximum offering price is $86.25 million. The company plans to list on the Nasdaq under the symbol, ACRS.

The offering is being made via Jefferies, Citigroup, and William Blair.

Aclaris Therapeutics is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated topical drugs to address significant unmet needs in dermatology.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Octagon opposes XFLT sub-adviser change ahead of July vote
• FDA accepts BioMarin's application for full approval of achondroplasia drug